The concept of suppressing renal glucose reabsorption in the proximal tubule to reduce plasma glucose levels and treat patients with diabetes has been elaborated more than 30 years ago when phlorizin, a relatively unselective inhibitor of sodium-glucose cotransporter 2 (SGLT2) was investigated [1]. Here, SLC5A2 is linked to diabetes mellitus.